Women’s health apps face urgent calls for stronger governance and transparency as sector rapidly expands

Jun 3
4 min read

The fast-growing market for women’s health apps is under increasing scrutiny, with experts warning that governance, transparency and regulatory clarity will be decisive in determining whether femtech delivers safe and effective care at scale.

A recent industry analysis highlights that while apps supporting menstrual health, fertility tracking, pregnancy care and menopause management are becoming widely used, inconsistent standards around data handling, clinical validation and accountability remain a significant barrier to trust and safety.

Sensitive data, uneven safeguards

Women’s health apps routinely process some of the most sensitive categories of personal health information, including menstrual cycles, sexual activity, fertility status and pregnancy outcomes.

Research from academic institutions including UCL and King’s College London has found that many widely used apps:

lack clear data deletion mechanisms
contain inconsistencies between privacy policies and actual data practices
may share sensitive data with third parties in ways users do not fully understand

In some cases, studies have shown that apps collect highly detailed reproductive data that could be linked to users’ identities or online activity, raising concerns about de-anonymisation and potential misuse.

These findings have intensified calls for stronger governance frameworks as women increasingly rely on digital tools for healthcare decisions outside traditional clinical settings.

Transparency as a foundation for trust

Experts argue that transparency is not simply a compliance requirement but a core determinant of user trust and clinical credibility.

Industry commentary in femtech development emphasises that users must clearly understand:

what data is collected
how it is processed
whether it is shared or monetised
and what risks may arise from use

Without this clarity, adoption risks being undermined even when apps provide clinically useful features.

This reflects a broader shift in digital health thinking: transparency is increasingly viewed as part of clinical safety, not just product design.

Governance gaps in a rapidly evolving sector

Regulating health apps remains complex because many products sit in a grey area between wellness tools and medical devices.

Under UK frameworks, apps may require:

Medicines and Healthcare products Regulatory Agency (MHRA) oversight if classified as medical devices
Care Quality Commission (CQC) registration if delivering regulated health services
evidence of clinical effectiveness aligned with NICE principles for higher assurance pathways

However, many women’s health apps do not clearly fall into regulated categories, creating what researchers describe as an “oversight gap” where accountability depends largely on voluntary compliance or platform self-regulation.

A wider challenge is that mobile health apps evolve rapidly, often updating features and data practices faster than regulatory systems can assess them.

Growing push for standards and “trust infrastructure”

Recent developments suggest the sector is moving towards formalised governance structures.

New initiatives in women’s health AI and femtech have begun to establish shared standards around:

data transparency
bias reduction
clinical safety
and accountability frameworks

These efforts reflect growing recognition that trust must be engineered into the ecosystem, rather than assumed.

Industry observers describe this as the emergence of a “trust layer” in women’s digital health - combining regulation, voluntary standards and platform accountability to guide how information is delivered and interpreted.

Why governance matters more in women’s health specifically

Women’s health apps are uniquely sensitive because they often involve:

reproductive autonomy and privacy
conditions that are under-diagnosed or historically under-researched
data that may carry legal or social risks depending on jurisdiction

Academic studies have warned that poor governance in this sector can expose users to risks including discrimination, surveillance or misuse of reproductive health data.

This makes governance failures not just technical issues, but potential safeguarding concerns.

The path forward: regulation, transparency and clinical validation

Experts broadly agree on three priorities for the sector:

1. Clearer regulatory classification: More consistent identification of when apps should be treated as medical devices rather than wellness tools.

2. Mandatory transparency standards: Plain-language disclosure of data use, third-party sharing and algorithmic decision-making.

3. Clinical evidence requirements: Stronger demands for published research and real-world validation of health outcomes before widespread adoption.

Under UK and international guidance, health apps are expected to demonstrate clinical effectiveness, safety and usability backed by evidence-based research, not just user engagement metrics.

Essential Modern Healthcare

Women’s health apps are becoming an essential part of modern healthcare delivery, but their rapid expansion has outpaced the governance systems meant to regulate them.

As the sector grows, transparency and regulatory clarity are increasingly seen not as optional safeguards, but as the foundation of safe, equitable and clinically credible digital health.

Without them, experts warn, the promise of femtech risks being undermined by the very data it relies on.